AURINIA PHARMACEUTICALS INC (AUPH) Stock Analyst Ratings

NASDAQ:AUPH • CA05156V1022

14.4 USD
0 (0%)
At close: Feb 20, 2026
14.4 USD
0 (0%)
After Hours: 2/20/2026, 8:17:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Buy % Consensus

78

ChartMill assigns a Buy % Consensus number of 78% to AUPH. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 17.05. This target is 18.39% above the current price.
  • AUPH was analyzed by 13 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about AUPH.
  • In the previous month the buy percentage consensus was at a similar level.
  • AUPH was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.

Related screens

Find peers with buy consensus above 85%
AUPH Historical Analyst RatingsAUPH Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 14.4013.1317.3417.0522.05 - -8.82% 20.42% 18.39% 53.13%

Related screens

Find peers 30% below price target
AUPH Current Analyst RatingAUPH Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5
Up and Down Grades
Date Firm Action Rating
2025-12-03 Leerink Partners Downgrade Outperform -> Market Perform
2025-11-07 Jefferies Upgrade Hold -> Buy
2025-11-05 RBC Capital Downgrade Outperform -> Sector Perform
2025-08-01 RBC Capital Maintains Outperform -> Outperform
2024-09-16 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-09-09 Cantor Fitzgerald Reiterate Overweight -> Overweight
2024-09-06 HC Wainwright & Co. Reiterate Buy -> Buy
2024-03-01 HC Wainwright & Co. Reiterate Buy -> Buy
2024-02-23 Cantor Fitzgerald Maintains Overweight -> Overweight
2024-02-22 HC Wainwright & Co. Maintains Buy -> Buy
2024-02-16 RBC Capital Maintains Outperform -> Outperform
2023-09-22 HC Wainwright & Co. Reiterate Buy -> Buy
2023-08-07 HC Wainwright & Co. Maintains Buy -> Buy
2023-07-06 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-05-03 HC Wainwright & Co. Reiterate Buy
2023-02-23 RBC Capital Reiterate Outperform
2023-01-04 RBC Capital Maintains Outperform
2022-11-07 HC Wainwright & Co. Maintains Buy
2022-11-04 Oppenheimer Downgrade Outperform -> Perform
2022-11-04 RBC Capital Maintains Outperform
2022-11-04 SVB Leerink Maintains Outperform
2022-08-09 HC Wainwright & Co. Maintains Buy
2022-08-08 Oppenheimer Maintains Outperform
2022-05-05 HC Wainwright & Co. Maintains Buy
2022-04-28 RBC Capital Maintains Outperform
2022-03-08 SVB Leerink Maintains Outperform
2022-03-01 RBC Capital Maintains Outperform
2022-02-23 RBC Capital Maintains Outperform
2021-12-10 Oppenheimer Upgrade Perform -> Outperform
2021-11-04 Oppenheimer Maintains Perform

AURINIA PHARMACEUTICALS INC / AUPH FAQ

What do analysts expect the price target to be for AURINIA PHARMACEUTICALS INC (AUPH)?

13 analysts have analysed AUPH and the average price target is 17.05 USD. This implies a price increase of 18.39% is expected in the next year compared to the current price of 14.4.


What is the consensus rating for AURINIA PHARMACEUTICALS INC (AUPH) stock?

The consensus rating for AURINIA PHARMACEUTICALS INC (AUPH) is 78.4615 / 100 . This indicates that analysts generally have a positive outlook on the stock.


What is the number of analysts for AUPH stock?

The number of analysts covering AURINIA PHARMACEUTICALS INC (AUPH) is 13.